Mulpleo (previously Lusutrombopag Shionogi) Den europeiske union - slovensk - EMA (European Medicines Agency)

mulpleo (previously lusutrombopag shionogi)

shionogi b.v. - lusutrombopag - trombocitopenija - antihemoragije - mulpleo je primerna za zdravljenje hude trombocitopenije pri odraslih bolnikih s kronično bolezen jeter, ki opravljajo invazivnih postopkov,.

Doptelet Den europeiske union - slovensk - EMA (European Medicines Agency)

doptelet

swedish orphan biovitrum ab (publ) - avatrombopag maleate - trombocitopenija - antihemoragije - doptelet je primerna za zdravljenje hude trombocitopenije pri odraslih bolnikih s kronično bolezen jeter, ki so načrtovani, da opravijo invaziven postopek. doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (itp) in adult patients who are refractory to other treatments (e. kortikosteroidi, imunoglobulini).

Pemetreksed TAD 100 mg prašek za koncentrat za raztopino za infundiranje Slovenia - slovensk - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pemetreksed tad 100 mg prašek za koncentrat za raztopino za infundiranje

pemetreksed - prašek za koncentrat za raztopino za infundiranje - pemetreksed 100 mg / 1 viala - pemetreksed

Pemetrexed Baxter Den europeiske union - slovensk - EMA (European Medicines Agency)

pemetrexed baxter

baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastična sredstva - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.